Novartis | NOVN - Debitur Perdagangan





Debitur Perdagangan Perubahan Tanggal
AbbVie USD 12.48B 110M 2026-03
Alcon AG USD 2.1B 90M 2026-06
Almirall EUR 196.15M 20.22M 2026-06
Amgen USD 10.23B 1.09B 2026-06
AstraZeneca USD 18.86B 972M 2026-06
Autolus Therapeutics Ltd USD 38.07M 37.71M 2026-03
Bayer EUR 18.7B 146M 2026-06
Biogen USD 1.79B 76.6M 2026-03
Bristol-Myers Squibb USD 13.83B 535M 2026-06
Eli Lilly USD 23.48B 2.3B 2026-06
Fresenius EUR 4.64B 862M 2026-06
Fresenius Medical Care EUR 3.47B 250.22M 2026-06
Genmab DKK 1.22B 192M 2026-06
Gilead Sciences USD 5.06B 314M 2026-06
GlaxoSmithKline GBP 8.07B 137M 2026-06
GRIFOLS EUR 1.19B 231M 2026-06
Hikma Pharmaceutical USD 1.08B 27M 2025-12
J&J USD 22.54B 1.21B 2026-03
Lakefront Biotherapeutics EUR 149.47M 95.44M 2026-06
Lonza CHF 1.78B 55M 2025-12
Merck EUR 4.95B 139M 2026-06
Merck USD 12.21B 435M 2026-03
Novartis USD 9.85B 252M 2026-06
Novartis USD 9.6B 2.69B 2026-03
Novo Nordisk DKK 114.94B 8.68B 2026-06
Orion EUR 543.8M 155.8M 2026-06
Pfizer USD 16.19B 19M 2026-06
Philips EUR 3.6B 70M 2026-06
Recordati EUR 778.71M 13.98M 2026-06
Regeneron Pharmaceuticals USD 6.57B 834.4M 2026-06
Roche Holding CHF 13.34B 1.44B 2026-06
Sanofi EUR 492M 10M 2026-06
UCB EUR 1.97B 54M 2025-12